Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3421942 | 1.00 | KIF11 (0.59) | KIF11ALDH1A1TSHRCYP2C9LMNA | |
| Ethane SCHEMBL27903947 | 0.97 | KIF11 (0.57) | KIF11ALDH1A1TSHRCYP2C9LMNA | |
| SCHEMBL26771321 | 0.93 | DHODH (0.54) | KIF11ALDH1A1TSHRCYP2C9RXRA | |
| SCHEMBL28102065 | 0.93 | DHODH (0.54) | KIF11ALDH1A1TSHRCYP2C9RXRA | |
| SCHEMBL18801808 | 0.93 | KIF11 (0.53) | KIF11ALDH1A1TSHRCYP2C9LMNA | |
| Biphenyl SCHEMBL27660679 | 0.92 | ALDH1A1 (0.53) | KIF11ALDH1A1TSHRLMNATYR | |
| Tert-Butylbenzene SCHEMBL10970404 | 0.92 | KIF11 (0.54) | KIF11ALDH1A1TSHRLMNATYR | |
| SCHEMBL22793707 | 0.91 | DHODH (0.57) | KIF11ALDH1A1RXRARXRBHSD17B2 | |
| P-Xylene SCHEMBL1419675 | 0.91 | TSHR (0.68) | KIF11ALDH1A1TSHRCYP2C9LMNA | |
| Bicarbonate SCHEMBL27587346 | 0.91 | CYP2C9 (0.57) | KIF11CYP2C9LMNARXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118724768-A | N-alkyl substituted nitrogen-containing compound and preparation method thereof | 武汉光化学技术研究院 | 2024-10-01 | — | — | CN | claimed |
| CN-118005471-A | Novel method for synthesizing 4-tert-butyl biphenyl by using palladium to catalyze tetrafluorothianthrene salt | 内蒙古大学 | 2024-05-10 | — | — | CN | claimed |
| CN-117603124-A | Double-main-body organic electroluminescent material and organic electroluminescent device | 吉林奥来德光电材料股份有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-105153241-B | Carbonylation ligands and their use in the carbonylation of ethylenically unsaturated compounds | 卢西特国际英国有限公司 | 2020-05-15 | — | — | CN | claimed |
| EP-2490291-B1 | LITHIUM SECONDARY BATTERY, AND NON-AQUEOUS ELECTROLYTIC SOLUTION FOR USE IN THE LITHIUM SECONDARY BATTERY | UBE INDUSTRIES (JP) | 2014-12-03 | — | — | EP | claimed |
| US-8377948-B2 | Antitumor agents and methods of their use | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-02-19 | — | — | US | claimed |
| EP-2490291-A1 | LITHIUM SECONDARY BATTERY, AND NON-AQUEOUS ELECTROLYTIC SOLUTION FOR USE IN THE LITHIUM SECONDARY BATTERY | Ube Industries, Ltd. (JP) | 2012-08-22 | — | — | EP | claimed |
| US-20120183846-A1 | LITHIUM SECONDARY BATTERY, AND NON-AQUEOUS ELECTROLYTIC SOLUTION FOR USE IN THE LITHIUM SECONDARY BATTERY | UBE INDUSTRIES, LTD. (JP) | 2012-07-19 | — | — | US | claimed |
| EP-1691441-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | claimed |
| US-7794885-B2 | Non-aqueous electrolytic solution and lithium secondary battery | UBE INDUSTRIES, LTD. (JP) | 2010-09-14 | — | — | US | claimed |
| CN-101553496-A | Novel carbonylation ligands and their use in the carbonylation of ethylenically unsaturated compounds | LUCITE INT UK LTD (GB) | 2009-10-07 | — | — | CN | claimed |
| US-20090048265-A1 | NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-02-19 | — | — | US | claimed |
| US-20080248399-A1 | Comprises an electrolyte salt in a non-aqueous solvent which contains a tert-alkylbenzene compound of high purity; battery improved in safety, excellent in cycle performance and storage performance at a high temperature, improved safety | UBE INDUSTRIES, LTD. (JP) | 2008-10-09 | — | — | US | claimed |
| EP-1361622-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERIES | UBE INDUSTRIES (JP) | 2008-06-04 | — | — | EP | claimed |
| US-20080050658-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERIES | UBE INDUSTRIES, LTD. (JP) | 2008-02-28 | — | — | US | claimed |
| US-20070082271-A1 | Non-aqueous electrolytic solution and lithium secondary battery | UBE INDUSTRIES, LTD. (JP) | 2007-04-12 | — | — | US | claimed |
| EP-1691441-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY | Ube Industries, Ltd. (JP) | 2006-08-16 | — | — | EP | claimed |
| US-20040121239-A1 | Nonaqueous electrolytic solution and lithium secondary batteries | UBE INDUSTRIES, LTD. (JP) | 2004-06-24 | — | — | US | claimed |
| EP-1361622-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERIES | Ube Industries, Ltd. (JP) | 2003-11-12 | — | — | EP | claimed |
| US-4271002-A | Calcium ion-selective electrodes and membrane for use therein | BECKMAN INSTRUMENTS, INC. (US) | 1981-06-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048265-A1 | NOVEL ANTITUMOR AGENTS AND METHODS OF THEIR USE | ADRB1, ADRA2A, ADRA1A | KIF11 2784/4885ALDH1A1 219/4885TSHR 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.